← Back to Search

Proteasome Inhibitor

Bortezomib for Multiple Myeloma

Phase 2
Waitlist Available
Led By Michele Donato, MD
Research Sponsored by Hackensack Meridian Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up participants will be followed post transplant for a minimum of 3 years, and after that may be monitored as part of the study indefinitely
Awards & highlights
No Placebo-Only Group

Summary

This trial is comparing two treatments for patients undergoing stem cell transplants. One treatment uses melphalan alone, while the other combines melphalan with bortezomib. Melphalan damages cancer cell DNA, and bortezomib disrupts protein breakdown in cancer cells, aiming to improve treatment outcomes. Bortezomib and melphalan have been used together in various studies to treat multiple myeloma, showing improved results.

Eligible Conditions
  • Multiple Myeloma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~participants will be followed post transplant for a minimum of 3 years, and after that may be monitored as part of the study indefinitely
This trial's timeline: 3 weeks for screening, Varies for treatment, and participants will be followed post transplant for a minimum of 3 years, and after that may be monitored as part of the study indefinitely for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Progression Free Survival Rate

Side effects data

From 2022 Phase 3 trial • 402 Patients • NCT03110562
50%
Thrombocytopenia
45%
Anaemia
39%
Nausea
29%
Diarrhoea
29%
Decreased appetite
27%
Weight decreased
24%
Vomiting
24%
Neuropathy peripheral
23%
Fatigue
21%
Neutropenia
21%
Cataract
15%
Asthenia
12%
Upper respiratory tract infection
11%
Constipation
11%
Pyrexia
8%
Oedema peripheral
8%
Pneumonia
6%
Insomnia
6%
Dehydration
6%
Back pain
6%
Leukopenia
6%
Bronchitis
6%
Dizziness
6%
Cough
6%
Lymphopenia
5%
Acute kidney injury
5%
Muscular weakness
5%
Abdominal pain
5%
Lower respiratory tract infection
3%
Sepsis
3%
Hyperglycaemia
3%
Pain in extremity
3%
Urinary tract infection
3%
Nasopharyngitis
3%
Hyponatraemia
3%
Toothache
3%
Disturbance in attention
3%
Cardiac failure
3%
Hypertension
2%
Septic shock
2%
Pulmonary contusion
2%
Peripheral swelling
2%
Infection
2%
Blood creatinine increased
2%
Paraesthesia
2%
Sudden death
2%
Respiratory syncytial virus infection
2%
Dyspepsia
2%
Syncope
2%
Cardiac failure acute
2%
Clostridium difficile infection
2%
Compression fracture
2%
Multiple fractures
2%
Haemoglobin decreased
2%
Myocardial infarction
2%
Cerebral haemorrhage
2%
C-reactive protein increased
2%
Ischaemic stroke
2%
Oropharyngeal pain
2%
Cognitive disorder
2%
Confusional state
2%
Influenza
2%
Osteonecrosis of jaw
2%
Taste disorder
2%
Hyperkalaemia
2%
Blood uric acid increased
2%
Depression
2%
Cerebrovascular accident
2%
Embolism
2%
Bronchitis viral
100%
80%
60%
40%
20%
0%
Study treatment Arm
SVdX Arm: Selinexor + Bortezomib + Dexamethasone
SdX Arm: Selinexor + Dexamethasone
SVd Arm: Selinexor + Bortezomib + Dexamethasone
Vd Arm: Bortezomib + Dexamethasone

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Treatment Arm BExperimental Treatment1 Intervention
Bortezomib: Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line. Bortezomib will be administered any time on day -4 and at least 20 hrs after the start of the melphalan infusion on day -1.
Group II: Treatment AActive Control1 Intervention
Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour. Melphalan will be given as a single dose (not split over 2 or more days) and given on day-1. Dosing will be based on body surface area calculated using actual body weight Stem cell infusion: Stem cell infusion will occur on day 0 and will be at least 20 hours after the infusion of melphalan. The infusion of peripheral blood stem cells will be done in accordance with the Blood and Marrow Transplant program standard operating procedures. Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day starting on day+3 then daily starting on day 9 until engraftment (at least).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bortezomib
2005
Completed Phase 3
~1410

Find a Location

Who is running the clinical trial?

Hackensack Meridian HealthLead Sponsor
135 Previous Clinical Trials
30,259 Total Patients Enrolled
20 Trials studying Multiple Myeloma
1,356 Patients Enrolled for Multiple Myeloma
Michele Donato, MDPrincipal InvestigatorJohn Theurer Cancer Center at Hackensack University Medical Center
5 Previous Clinical Trials
257 Total Patients Enrolled
2 Trials studying Multiple Myeloma
181 Patients Enrolled for Multiple Myeloma
~4 spots leftby Dec 2025